ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

QTRX Quanterix Corporation

16.78
-0.44 (-2.56%)
After Hours
Last Updated: 22:30:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Quanterix Corporation NASDAQ:QTRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.44 -2.56% 16.78 16.53 21.66 17.1799 16.65 17.10 220,381 22:30:00

Quanterix to Participate in Fireside Chat at Goldman Sachs Annual Global Healthcare Conference

07/06/2023 9:00pm

Business Wire


Quanterix (NASDAQ:QTRX)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Quanterix Charts.

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs Annual Global Healthcare Conference on June 14, 2023 at 10:40 a.m., PT. The presentation will be available virtually and listeners can register here: https://cc.webcasts.com/gold006/061223a_js/?entity=12_GUSDLRC. The presentation will be available following the conference on Quanterix’s website here: ir.quanterix.com.

To learn more about Quanterix, visit www.quanterix.com/about. To learn more about Quanterix’s Simoa® technology, visit: https://www.quanterix.com/technology.

About Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,000 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

Media: PAN Communications Maya Nimnicht 510-334-6273 quanterix@pancomm.com

Investor Relations: Ed Joyce (610) 306-9917 ir@quanterix.com

1 Year Quanterix Chart

1 Year Quanterix Chart

1 Month Quanterix Chart

1 Month Quanterix Chart

Your Recent History

Delayed Upgrade Clock